Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
